Treatment for Preventing Immunological Complications using Drug-Free Carriers
|
Categories |
Drug Allergy, Drug Delivery, Nano-pharmaceuticals |
|
Development Stage |
TRL4, Successfully tested in large animals |
|
Patent Status |
US and Europe patent |
|
Opportunity |
Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients |
Highlights
-
Intravenous infusion of certain drugs and diagnostic agents that contain particles in the range
10-9-10-6m (particulate medicines PCM) produce pseudo-allergic reactions that appear to be similar to those caused by pollen or foods, but in fact differ from those reactions. -
PCM reactions appear to be initiated by the complement system (C) of the immune system.
-
Liposomes, micelles, and other particulate drug carriers which do not carry C inhibitors on their surfaces activate these hypersensitive reactions.
Our Innovation
Treatment with a placebo, drug-free carrier, prior to administration of particulate medicines to prevent allergic reactions to the medicines
Key Features
-
Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
-
Toxicology tests for this technology are very simple
The Opportunity
Opportunity to incorporate new technology with minimal regulatory process
Researcher Information biochemistry.huji.ac.il/faculty_barenholz.asp, research.ekmd.huji.ac.il/researchers.asp?id=166, nanoscience.huji.ac.il/researchers/barenholz.htm
